Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Singapore Health Sciences Authority (HSA) has approved Emergent's product license application for the marketing and sale of BioThrax® (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.

"Emergent is pleased with this development as it continues to grow its presence in the Pacific Rim," said Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions. "With HSA approval of BioThrax, we look forward to initiating discussions with the government of Singapore, as well as other allied governments that recognize HSA registered products such as Brunei, to help protect their constituents against the threat of anthrax as a biological weapon."

HSA is the statutory board of the Singapore Ministry of Health that administers the country's regulatory framework for pharmaceuticals, complementary medicines, medical devices and other health products. Its vision is to be the leading innovative authority that protects and advances national health and safety in Singapore.

About BioThrax

BioThrax is the only FDA-licensed vaccine for the prevention of anthrax infection. It is indicated for the active immunization of adults who are at high risk of exposure to anthrax. BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis. To date, Emergent has delivered over 42 million doses of BioThrax to the U.S. government and continues to deliver additional doses under active procurement contracts. Since 1998, over 10 million doses have been administered to more than 2.5 million military personnel.

Emergent BioSolutions Inc.